Serine-Glycine-One-Carbon Metabolism: The Hidden Achilles Heel of <i>MYCN</i>-Amplified Neuroblastoma?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31371280.
- Also identified by DOI 10.1158/0008-5472.CAN-19-1816.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of <i>Cancer Research</i>, Xia and colleagues show that MYC-induced metabolic reprograming results in dependency on the serine-glycine-one-carbon (SGOC) metabolic pathway in neuroblastoma. This occurs through MYCN and ATF4 activation of the SGOC biosynthetic pathway in <i>MYCN</i>-amplified cells. Furthermore, inhibition of <i>de novo</i> serine synthesis generates metabolic stress in <i>MYCN</i>-amplified neuroblastoma cells, causing cell-cycle arrest and autophagy. Together, these data suggest that the SGOC pathway is an attractive therapy target in neuroblastoma.<i>See related article by Xia et al., p. 3837</i>.
Medical subject headings
- Neuroblastoma
- Oncogene Proteins